🇺🇸 Lipacreon in United States

149 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 149

Most-reported reactions

1. Pancreatic Carcinoma — 32 reports (21.48%)
2. Diarrhoea — 20 reports (13.42%)
3. Decreased Appetite — 18 reports (12.08%)
4. Anaemia — 16 reports (10.74%)
5. Cancer Pain — 14 reports (9.4%)
6. Malaise — 11 reports (7.38%)
7. Malignant Neoplasm Progression — 10 reports (6.71%)
8. Pneumonia — 10 reports (6.71%)
9. Hypoalbuminaemia — 9 reports (6.04%)
10. Nausea — 9 reports (6.04%)

Source database →

Frequently asked questions

Is Lipacreon approved in United States?

Lipacreon does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Lipacreon in United States?

Mylan Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.